VentriPoint Diagnostics Ltd Total Assets
VentriPoint Diagnostics Ltd total assets. Based on the latest financial reports, VentriPoint Diagnostics Ltd (VPT) holds total assets worth CA$472.08K CAD (≈ $341.50K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VentriPoint Diagnostics Ltd (VPT) total market value for the company's overall valuation and market capitalisation.
Total Assets of VentriPoint Diagnostics Ltd (2005–2025)
Total assets of VentriPoint Diagnostics Ltd from 2005 to 2025. This chart illustrates how VentriPoint Diagnostics Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of VentriPoint Diagnostics Ltd for real-time trading data and today's change.
VentriPoint Diagnostics Ltd - Asset Composition Analysis
VentriPoint Diagnostics Ltd Total Assets Breakdown (December 2025)
VentriPoint Diagnostics Ltd total assets breakdown as of December 2025. VentriPoint Diagnostics Ltd's total assets of CA$472.08K consist of 74.1% current assets and 26.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 11.7% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how VentriPoint Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore VentriPoint Diagnostics Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VentriPoint Diagnostics Ltd's current assets represent 74.1% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2025, down from 99.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
VentriPoint Diagnostics Ltd Competitors by Total Assets
Key competitors of VentriPoint Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
VentriPoint Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.14 | 1.32 |
| Quick Ratio | 0.08 | 0.14 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-4.12 Million | CA$-2.95 Million | CA$667.15K |
VentriPoint Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between VentriPoint Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.13 |
| Latest Market Cap to Assets Ratio | 23.64 |
| Asset Growth Rate (YoY) | -28.3% |
| Total Assets | CA$472.08K |
| Market Capitalization | $11.16 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VentriPoint Diagnostics Ltd's assets at a significant premium (23.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: VentriPoint Diagnostics Ltd's assets decreased by 28.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VentriPoint Diagnostics Ltd (2005–2025)
The table below shows the annual total assets of VentriPoint Diagnostics Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$472.08K ≈ $341.50K |
-28.26% |
| 2024-12-31 | CA$658.02K ≈ $476.00K |
-65.06% |
| 2023-12-31 | CA$1.88 Million ≈ $1.36 Million |
-68.49% |
| 2022-12-31 | CA$5.98 Million ≈ $4.32 Million |
-37.38% |
| 2021-12-31 | CA$9.54 Million ≈ $6.90 Million |
+1090.77% |
| 2020-12-31 | CA$801.57K ≈ $579.84K |
+155.05% |
| 2019-12-31 | CA$314.28K ≈ $227.35K |
-32.63% |
| 2018-12-31 | CA$466.49K ≈ $337.45K |
-72.72% |
| 2017-12-31 | CA$1.71 Million ≈ $1.24 Million |
+154.27% |
| 2016-12-31 | CA$672.50K ≈ $486.48K |
-69.15% |
| 2015-12-31 | CA$2.18 Million ≈ $1.58 Million |
+343.26% |
| 2014-12-31 | CA$491.74K ≈ $355.71K |
-35.36% |
| 2013-12-31 | CA$760.73K ≈ $550.30K |
-35.25% |
| 2012-12-31 | CA$1.17 Million ≈ $849.89K |
-51.91% |
| 2011-12-31 | CA$2.44 Million ≈ $1.77 Million |
+43.60% |
| 2010-12-31 | CA$1.70 Million ≈ $1.23 Million |
+727.09% |
| 2009-12-31 | CA$205.68K ≈ $148.79K |
-46.96% |
| 2008-12-31 | CA$387.79K ≈ $280.52K |
-87.50% |
| 2007-12-31 | CA$3.10 Million ≈ $2.24 Million |
+356.17% |
| 2006-12-31 | CA$679.97K ≈ $491.88K |
-3.01% |
| 2005-12-31 | CA$701.04K ≈ $507.13K |
-- |
About VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional m… Read more